159 related articles for article (PubMed ID: 37335031)
1. Efficacy and Safety of Switching to Dolutegravir/Lamivudine in Virologically Suppressed People Living with HIV-1 Aged Over 65 Years.
Calza L; Colangeli V; Legnani G; Cretella S; Bon I; Viale P
AIDS Res Hum Retroviruses; 2024 Feb; 40(2):73-79. PubMed ID: 37335031
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies.
Walmsley S; Smith DE; Górgolas M; Cahn PE; Lutz T; Lacombe K; Kumar PN; Wynne B; Grove R; Bontempo G; Moodley R; Okoli C; Kisare M; Jones B; Clark A; Ait-Khaled M
AIDS Res Ther; 2024 Mar; 21(1):17. PubMed ID: 38515183
[TBL] [Abstract][Full Text] [Related]
3. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Borghetti A; Lombardi F; Gagliardini R; Baldin G; Ciccullo A; Moschese D; Emiliozzi A; Belmonti S; Lamonica S; Montagnani F; Visconti E; De Luca A; Di Giambenedetto S
BMC Infect Dis; 2019 Jan; 19(1):59. PubMed ID: 30654739
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.
Rojas J; de Lazzari E; Negredo E; Domingo P; Tiraboschi J; Ribera E; Abdulghani N; Puig J; Mateo MG; Podzamczer D; Gutierrez MM; Paredes R; Clotet B; Gatell JM; Blanco JL; Martínez E;
Lancet HIV; 2021 Aug; 8(8):e463-e473. PubMed ID: 34358497
[TBL] [Abstract][Full Text] [Related]
6. Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding.
Ciccullo A; Borghi V; Giacomelli A; Cossu MV; Sterrantino G; Latini A; Giacometti A; De Vito A; Gennari W; Madeddu G; Capetti A; d'Ettorre G; Mussini C; Rusconi S; Di Giambenedetto S; Baldin G
J Acquir Immune Defic Syndr; 2021 Nov; 88(3):234-237. PubMed ID: 34446677
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
Osiyemi O; De Wit S; Ajana F; Bisshop F; Portilla J; Routy JP; Wyen C; Ait-Khaled M; Leone P; Pappa KA; Wang R; Wright J; George N; Wynne B; Aboud M; van Wyk J; Smith KY
Clin Infect Dis; 2022 Sep; 75(6):975-986. PubMed ID: 35079789
[TBL] [Abstract][Full Text] [Related]
8. Dolutegravir Plus Lamivudine as Initial Therapy for HIV-1 Infected and ARV-naïve Patients in West China, 24-Weeks Results of a Preliminary Real-world Study.
Hui X; Gan X; Li Q; Sun W
Curr HIV Res; 2022; 20(3):222-227. PubMed ID: 35570525
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness, Weight Changes, and Metabolic Outcomes on Switch to Generic Dolutegravir/Lamivudine Among People with HIV in Western India: An Observational Study.
Pujari S; Gaikwad S; Panchawagh S; Chitalikar A; Joshi K; Rohekar C; Dabhade D; Bele V
AIDS Res Hum Retroviruses; 2024 Apr; 40(4):204-215. PubMed ID: 38063004
[TBL] [Abstract][Full Text] [Related]
10. Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.
Moyle G; Assoumou L; de Castro N; Post FA; Curran A; Rusconi S; De Wit S; Stephan C; Raffi F; Johnson M; Masia M; Vera J; Jones B; Grove R; Fletcher C; Duffy A; Morris K; Pozniak A;
Lancet HIV; 2024 Mar; 11(3):e156-e166. PubMed ID: 38417976
[TBL] [Abstract][Full Text] [Related]
11. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
12. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
Hidalgo-Tenorio C; Cortés LL; Gutiérrez A; Santos J; Omar M; Gálvez C; Sequera S; Jesús SE; Téllez F; Fernández E; García C; Pasquau J
Medicine (Baltimore); 2019 Aug; 98(32):e16813. PubMed ID: 31393412
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.
Maggiolo F; Gulminetti R; Pagnucco L; Digaetano M; Cervo A; Valenti D; Callegaro A; Mussini C
BMC Infect Dis; 2022 Oct; 22(1):782. PubMed ID: 36224538
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV.
Dueñas-Gutiérrez C; Buzón L; Pedrero-Tomé R; Iribarren JA; De Los Santos I; De la Fuente S; Pousada G; Moran MA; Moreno E; Ferreira E; Gómez J; Troya J
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112915
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
van Wyk J; Ajana F; Bisshop F; De Wit S; Osiyemi O; Portilla Sogorb J; Routy JP; Wyen C; Ait-Khaled M; Nascimento MC; Pappa KA; Wang R; Wright J; Tenorio AR; Wynne B; Aboud M; Gartland MJ; Smith KY
Clin Infect Dis; 2020 Nov; 71(8):1920-1929. PubMed ID: 31905383
[TBL] [Abstract][Full Text] [Related]
16. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients.
Baldin G; Ciccullo A; Rusconi S; Capetti A; Sterrantino G; Colafigli M; d'Ettorre G; Giacometti A; Cossu MV; Borghetti A; Gennari W; Mussini C; Borghi V; Di Giambenedetto S
Int J Antimicrob Agents; 2019 Dec; 54(6):728-734. PubMed ID: 31521809
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
Lagi F; Giacomelli A; Borghi V; Ciccullo A; Taramasso L; Madeddu G; D'Ettorre G; Giacometti A; Ducci F; De Vito A; Pincino R; Di Giambenedetto S; Mussini C; Antinori S; Sterrantino G
J Med Virol; 2023 Oct; 95(10):e29149. PubMed ID: 37805832
[TBL] [Abstract][Full Text] [Related]
18. Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.
Maggiolo F; Gulminetti R; Pagnucco L; Digaetano M; Benatti S; Valenti D; Callegaro A; Ripamonti D; Mussini C
BMC Infect Dis; 2017 Mar; 17(1):215. PubMed ID: 28302065
[TBL] [Abstract][Full Text] [Related]
19. Short Communication: Efficacy and Safety of Dolutegravir Plus Lamivudine as a First-Line Regimen in Clinical Practice.
Ciccullo A; Baldin G; Dusina A; Cossu MV; Lombardi F; Borghetti A; Capetti A; Di Giambenedetto S
AIDS Res Hum Retroviruses; 2021 Jun; 37(6):486-488. PubMed ID: 33587008
[TBL] [Abstract][Full Text] [Related]
20. Three-year efficacy of switching to dolutegravir plus lamivudine: A real-world study.
Palmier E; De Miguel R; Montejano R; Busca C; Micán R; Ramos L; Cadiñanos J; Serrano L; Bernardino JI; Pérez-Valero I; Valencia E; Arribas JR; Montes ML; González-García J; Martín-Carbonero L
HIV Med; 2023 Sep; 24(9):1013-1019. PubMed ID: 37194419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]